- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05791201
A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
February 5, 2024 updated by: Vertex Pharmaceuticals Incorporated
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-264 in Subjects With Type 1 Diabetes Mellitus
The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).
Study Overview
Study Type
Interventional
Enrollment (Estimated)
17
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Medical Information
- Phone Number: 617-341-6777
- Email: medicalinfo@vrtx.com
Study Locations
-
-
-
Edmonton, Canada
- Recruiting
- University of Alberta, Edmonton
-
Toronto, Canada
- Recruiting
- Toronto General Hospital (TGH)
-
-
-
-
-
Dresden, Germany
- Recruiting
- Dresden Center for Islet Transplantation
-
-
-
-
-
Milan, Italy
- Recruiting
- IRCCS Ospedale San Raffaele
-
-
-
-
-
Leiden, Netherlands
- Recruiting
- Leiden University
-
-
-
-
-
Geneve, Switzerland
- Recruiting
- Hopiteaux Universitaires de Geneve
-
-
-
-
-
Headington, United Kingdom
- Recruiting
- Churchill Hospital
-
-
-
-
Florida
-
Miami, Florida, United States, 33136
- Recruiting
- UHealth Diabetes Research Institute
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- Recruiting
- University of Chicago
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Hospital of the University of Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Recruiting
- University of Pittsburgh Medical Center Montefiore
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
- Clinical history of T1D with greater than or equal to (>=) 5 years duration
- Participant is on a stable diabetic treatment
- Consistent use of continuous glucose monitoring (CGM) for at least 4 weeks before Screening and willingness to use CGM for the duration of the study
Key Exclusion Criteria:
- Prior islet cell transplant, organ transplant, or cell therapy
Other protocol defined Inclusion/Exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: VX-264
|
Allogeneic human stem cell-derived islets.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Part A and Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: From Day 1 up to 24 months
|
From Day 1 up to 24 months
|
Part B and Part C: Change in Peak C-peptide during Mixed-Meal Tolerance Test (MMTT)
Time Frame: From Baseline and at Day 90
|
From Baseline and at Day 90
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Part C: Change in peak C-peptide during MMTT
Time Frame: From Baseline up to 24 months
|
From Baseline up to 24 months
|
Part C: Change in Average Total Daily Insulin Dose
Time Frame: From Baseline up to 24 months
|
From Baseline up to 24 months
|
Part C: Proportion of Participants who are Insulin Independent at One Point in Time
Time Frame: From Day 180 up to Day 365
|
From Day 180 up to Day 365
|
Part C: Change in HbA1c values
Time Frame: From Baseline up to 24 months
|
From Baseline up to 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 16, 2023
Primary Completion (Estimated)
May 1, 2026
Study Completion (Estimated)
May 1, 2026
Study Registration Dates
First Submitted
March 16, 2023
First Submitted That Met QC Criteria
March 16, 2023
First Posted (Actual)
March 30, 2023
Study Record Updates
Last Update Posted (Actual)
February 7, 2024
Last Update Submitted That Met QC Criteria
February 5, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VX22-264-101
- 2022-003318-35 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesTerminated
Clinical Trials on VX-264
-
Regor Pharmaceuticals Inc.Active, not recruiting
-
Vertex Pharmaceuticals IncorporatedCompleted
-
Vertex Pharmaceuticals IncorporatedCompletedCystic FibrosisUnited States
-
Vertex Pharmaceuticals IncorporatedActive, not recruitingCystic FibrosisUnited States, Australia, Germany, Sweden, Switzerland, France, Netherlands, United Kingdom
-
Vertex Pharmaceuticals IncorporatedActive, not recruitingCystic FibrosisUnited States, Spain, United Kingdom, Belgium, Netherlands, Denmark, Israel, New Zealand, France, Australia, Ireland, Germany, Sweden, Canada, Czechia, Switzerland, Portugal, Italy, Austria, Hungary, Norway, Poland, Greece
-
Vertex Pharmaceuticals IncorporatedRecruiting
-
Vertex Pharmaceuticals IncorporatedEnrolling by invitationCystic FibrosisUnited States, Australia, Germany, Sweden, Switzerland, France, Netherlands, United Kingdom
-
Vertex Pharmaceuticals IncorporatedEnrolling by invitationCystic FibrosisUnited States
-
BiocadCompleted